The tyrosine-protein phosphatase non-receptor type 22 (PTPN22) gene was recently identified as an important genetic susceptibility factor in several autoimmune diseases. The increased risk has been broadly explained by the 1858T-allele (rs2476601). As two smaller studies on Addison's disease (AD) have shown diverging results, we aimed to elucidate the predisposing effect of the single-nucleotide polymorphism (SNP) 1858CT in a larger population of AD patients, especially focusing on the AD patients with known autoimmune etiology. We also screened for unknown rare or common variants in the PTPN22 gene that could predispose for AD. The case-control study of Norwegian AD patients (n ¼ 332) and controls (n ¼ 990) showed a significant association between autoimmune AD (n ¼ 302) and the PTPN22 1858T risk allele (P ¼ 0.016). The association of AD with 1858T was supported by a meta-analysis combining our genotype data with that of others published previously (P ¼ 0.003). The mutation screening of PTPN22 in AD patients (n ¼ 332) and controls (n ¼ 112) revealed eight missense variants, five of which have not been reported previously. In conclusion, the 1858T-allele is a PTPN22 genetic susceptibility factor for autoimmune AD. Other rare variants in PTPN22 do occur, and may also be involved in the pathogenesis.
Introduction
Autoimmune diseases affect up to 5% of the population and are among the 10 most common causes of death in women. 1 They are characterized by the loss of selftolerance causing immune-mediated tissue destruction. 2 Autoimmune Addison's disease (AD) occurs due to autoimmune destruction of the adrenal cortex. Approximately half of the patients have additional autoimmune components. 3 AD with concomitant thyroid autoimmunity and/or type I diabetes is the most common syndrome referred to as autoimmune polyendocrine syndrome type II (APS II). 4 It has long been suspected that several of the genetic determinants may be identical in different autoimmune diseases. This hypothesis is based upon observations of clustering of different autoimmune diseases in families, 5 as well as overlapping linkage peaks in meta-analyses of families with different autoimmune diseases. 6 There is also molecular genetic evidence to support this; for example, human leukocyte antigen (HLA) complex genes 7 and cytotoxic T-lymphocyte-associated protein 4 are associated with numerous autoimmune conditions. 8, 9 Tyrosine-protein phosphatase non-receptor type 22 encoded by the PTPN22 gene has recently been claimed to be the second most important genetic susceptibility factor in autoimmune diseases, after the HLA gene complex. PTPN22 encodes a tyrosine phosphatase, also called Lyp, which modulates T-cell activation and signaling events in a way that may trigger development of autoimmune disease. 10 A C to T substitution in nucleotide position 1858, which results in the substitution of arginine (R) with tryptophan (W) (R620W), has been suggested to be a gainof-function variant. 10, 11 The T-allele of this single-nucleotide polymorphism (SNP) has been demonstrated to moderately increase the susceptibility to several autoimmune disorders, for example, type I diabetes, For this reason, we decided to undertake a larger and statistically more powerful study encompassing a total of 368 AD patients and 1128 healthy controls from Norway and UK to determine whether the PTPN22 1858CT variant is associated with AD. Three hundred and two of the Norwegian patients had a verified autoimmune etiology, either by the detection of autoantibodies in their blood or by a secondary autoimmune diagnosis, and were, therefore, of special interest. A meta-analysis of Caucasian cohorts was performed to elucidate the risk of this SNP across populations. Furthermore, in light of the extreme proneness to autoimmunity observed in AD patients, we hypothesized that there may also be other, as yet unidentified, rare variants in this gene, which may predispose to AD. The involvement of infrequent mutations would also be in line with AD, being a rare autoimmune disorder compared to the other diseases previously analyzed for PTPN22 polymorphisms. Being a rare disorder, the common variant -common disease hypothesis, 21 which postulates that most genetic susceptibility factors in common complex disorders are common variants, is less likely to be applicable. Previous screenings for mutations throughout the PTPN22 gene are, to our knowledge, limited to 94 type I diabetes patients, 22 64 parents of type I diabetes patients, 23 20 psoriasis patients, 24 48 rheumatoid arthritis patients, 25 and 35 healthy controls. 26 To this end we resequenced the coding part of the gene in 332 Norwegian patients and 112 healthy controls to clarify if there were additional coding variants in PTPN22 that may predispose for AD. To our knowledge, this is the most comprehensive sequence analysis of PTPN22 performed in a study of any autoimmune disease.
Materials and methods

Patients and controls
Three hundred and thirty-two Caucasian patients with AD (206 women, 126 men) were recruited from the Norwegian registry of organ-specific autoimmune diseases (Supplementary Table 1 27 Informed consent has been obtained by all participants.
Measurement of autoantibodies
Antibodies against 21OH, GAD and SCC were assayed by a radioimmunoassay against 35S-labeled recombinant human autoantigens expressed by in vitro transcription and translation, as described by Ekwall et al. 28 Positivity for the assays was governed by whether the test absorbance was greater than 3 SD above the negative control value.
Single-nucleotide polymorphism genotyping
The 1858CT (rs2476601) SNP was genotyped by standard conditions using a Custom TaqMan s SNP Genotyping Assay, and analyzed on ABI PRISM s 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Secondary to the mutation screening, the same technique was used to analyze five of the missense variants in an extended number of controls to define their frequency in the general population. Direct sequencing, as described below, was performed for the same purpose for the other two missense variants.
Mutation screening
The BigDye s terminator v3.1 chemistry (Applied Biosystems) was used for bidirectional sequencing of all 21 exons of the PTPN22 gene, in addition to the 5 0 UTR, 3 0 UTR and intron -exon boundaries in all 332 Norwegian AD patients and 112 anonymous Norwegian blood donors (randomly chosen from the 990 blood donors analyzed for the SNP 1858CT). Primers were designed using Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), 29 and optimized with 601C annealing temperature to enable the polymerase chain reactions (PCRs) to be run simultaneously in 5 ml reactions in 384-well plates. PCR clean-up was performed with Exo-SAP (USB Corporation, Cleveland, OH, USA), while the sequence reactions were purified using Montaget SEQ384 filter plates on a vacuum manifold (Millipore, Bedford, MA, USA) according to recommendations from the manufacturers. Sequences were read by an ABI3730 DNA analyzer and analyzed using the SeqScape v2.1.1 software (Applied Biosystems). Unsuccessful sequences were redone obtaining 100% coverage. All identified novel coding variants were assessed for functional importance using PolyPhen (http://genetics.bwh.harvard. edu/pph/), 30 a bioinformatic tool for prediction of possible impact of an amino acid substitution of a protein, based on both phylogenetic and structural information. Any changes in splicing-site motifs due to nucleotide substitutions close to exon -intron junctions were predicted by the use of ESEfinder v3.0 (http://rulai.cshl.edu/cgi-bin/tools/ ESE3/esefinder.cgi). 
Meta-analysis
PubMed (http://www.ncbi.nlm.nih.gov/) was searched using the search terms 'PTPN22', 'Lyp' and 'Addison's'. All studies found, who gave genotype data for 1858CT, were included in a meta-analysis together with our own data from the present study. The two English cohorts were recruited from different geographical areas. Breslow -Day homogeneity of OR analysis and Mantel -Haenszel common OR estimation were performed using SPSS v.14.0.
Results
Association analyses of the PTPN22 SNP 1858CT
In the Norwegian population, we found a significant association between the PTPN22 1858T-allele and AD patients with known autoimmune etiology (n ¼ 302) with an OR 16 Breslow -Day analysis did not detect any significant heterogeneity of OR (P ¼ 0.554) between the populations. The meta-analysis confirmed the association of the 1858T risk allele with AD with a common OR of 1.36 (95% CI: 1.11 -1.66, P ¼ 0.003) ( Table 2) .
Mutation screening of PTPN22
The mutation screening of the PTPN22 gene revealed eight missense variants, of which five have not been reported previously (Table 3) . Moreover, ten novel non-coding variants were found (Supplementary Table 2 ). An additional novel variant was detected in the 3 0 UTR. Three intronic variants were positioned within four bases away from an exon -intron junction, and might, therefore, affect splicing. We only had access to leukocyte RNA from one patient with a nucleotide change close to an exon-intron junction; the c.197À4 in intron 2 adjacent to exon 3. Analysis to elucidate if this variant caused skipping of the exon 3 did, however, not show such a consequence in this patient's leukocytes (data not shown). All novel base changes were rare variants with a minor allele frequency less than 1% in the normal population. Segregation of the variants in the patients' families could not be investigated since samples from family members were unavailable.
Eight known non-coding or 3 0 UTR SNPs were located inside the sequenced regions thereby providing genotypes in the sequenced individuals. These were rs3789612, rs1217419, rs1217418, rs1599971, rs3761935, rs34209542, rs1217412 and rs3811021. They were all in HardyWeinberg Equilibrium. Neither of these SNPs showed significant difference in genotype or allele distributions between the patient group and control group using standard w 2 tests. Haplotypes of all SNPs with minor allele frequency (MAF) 45%, that is, excluding rs3789612 and rs34209542, were constructed for both cases and controls (Supplementary Table 3 ). As noted earlier, the 1858T allele was observed to occur on a single common haplotype. 22, 25 These data show that the 112 controls, randomly selected for sequencing, have an unusually high frequency of the 1858T variant (14.3%) compared to the wider population (10.8%). Neither of the haplotypes displayed any association with AD in the dataset where we had haplotype data.
Discussion
Our data comparing Norwegian AD patients and healthy controls demonstrated a significant association of autoimmune AD to the PTPN22 1858T allele, underpinning the coupling of autoimmunity to this SNP. The meta-analysis 19 Moreover, these results let autoimmune AD fall into the line of autoimmune diseases previously shown to be associated with this SNP. We screened the PTPN22 gene to clarify if there are any common unknown variants or any rare mutations in PTPN22 that may predispose for AD. A total of 28 variations were found, 16 of them were novel, including 5 missense, 1 in the 3 0 UTR and 10 located in introns. This represents the largest screening for PTPN22 mutations in any disease, and also included 112 healthy controls. Four of the seven missense variants listed in Table 3 were predicted to be damaging to the protein function by PolyPhen. 30 Interestingly, the frequency of missense variants predicted to be damaging were slightly higher in the patient group compared to the controls. Conversely, there was an opposite weak tendency for variants predicted to be benign to be more frequent in the controls. The main contribution came from R263Q that was detected by the heterozygosity rates of 2.4 and 3.9% in Norwegian AD cases and controls, respectively. The three non-coding variants located closest to an exon -intron junction, that is, c.197À4, c.828 þ 4 and c.2882À2 were subjected to in silico analysis for prediction of splice sites and binding of serine/arginine-residue proteins (SR proteins) using the program ESEfinder v3.0. 31 Compared to the respective wild-type sequence, the nucleotide substitutions were predicted to have the following motif changes: the mutated allele c.197À4G had two additional predicted SR protein-binding sites (SC35 and SRp55), and the mutant variant c.2282À2C lacked a 3 0 U2 splicing site. These predicted differences of binding of splicing factors in the two PTPN22 variants may suggest that they can affect normal splicing. In vitro analysis of c.197À4 did, however, not prove any exon skipping in leukocytes, but we cannot rule out that the variant may influence gene splicing in other tissues. However, any pathogenic effect of these variants is, therefore, at present speculative, and needs to be confirmed functionally.
PTPN22 is a downregulator of the immune system by turning off the T-cell receptor (TCR) signaling when c-src tyrosine kinase (CSK) is bound to the SH3-domain of PTPN22. The PTPN22 1858T allele has been suggested to be a gain-of-function variant by increasing the enzyme activity, 11 and also by disrupting the binding of CSK to PTPN22. 12, 15 Two explanations of the increased risk of autoimmunity in carriers of this allele have been proposed: they may have a higher TCR-signaling threshold and require stronger TCR signals for activation, thereby introducing a relative resistance to thymic deletion of autoreactive T cells, 11 or they may have reduced TCR signaling, leading to less effective T-regulatory cell activity. 35 The effect of the rare variants detected in AD patients in the present study on the function of PTPN22 is difficult to predict. Some of the variants may modulate catalytic function, others the binding to CSK or other potential binding partners, 36 with a potential result of affected TCR signaling. We examined family history of individuals with rare PTPN22 variants; however, no firm conclusions can be drawn, largely owing to the small number of individuals involved (data not shown).
Focusing on the spectrum of variations (Supplementary Figure 1) detected in PTPN22 in this study 10 of the novel variants (63%) were singletons (ie heterozygotes observed in a single individual) and the rest of the novel variants were all rare (ie MAF o5%), demonstrating the fact that the number of rare SNPs increases with depth of sequencing, whereas the number of common variants will plateau as most of them are already identified. 37 The sequencing of PTPN22 in a total of 888 chromosomes revealed a two-fold density of variations in non-coding sequence of PTPN22 compared to the coding sequence of the gene, with a density of one variation per 166 and 333 bp, respectively. Even though our study and the HapMap ENCODE project diverge on the basis of selection of sample population and selection of sequence to be screened, it is noteworthy that our frequency variation spectrum and SNP density (compared to their overall SNP-density of one per 279 bp) are very similar. Anyway, our data comprise a large sample size for mutation screening of a single locus and may, therefore, contribute to our understanding of SNP density in genes.
To conclude, this study adds autoimmune AD to the list of autoimmune diseases, where PTPN22 1858T is a genetic susceptibility factor. The comprehensive resequencing of PTPN22 did not demonstrate any novel common coding SNP predisposing to AD in Norwegian patients, but our findings show that a number of novel infrequent or private mutations in PTPN22 do occur, and bioinformatic analyses suggest that they may affect PTPN22 function and possibly susceptibility to AD. However, their contribution to the AD phenotype needs to be further elucidated by functional studies.
